When do biologic drug patents expire and when will biosimilars launch?

US Patent 6,309,650: What Claims Does It Cover and How Does Its US Patent Landscape Shape Freedom-to-Operate?

US Patent 6,309,650 (granted Oct. 30, 2001) anchors a US claim set that remains relevant for freedom-to-operate (FTO) analysis primarily through (i) the original asserted claim scope at issuance, (ii) related continuations/divisionals and continuations-in-part that may have expanded claim coverage, and (iii) later refinement patents by the same assignees or competitors on the same technical core. Without the patent’s full specification and claim text, a claim-by-claim legal construction or an expiration/term and exclusivity mapping cannot be produced accurately, and the landscape cannot be tied to the correct CPC/US classes or to actual citing and family members.

No response is provided because the necessary claim text, assignee, publication family, and prosecution history details required to deliver a complete and accurate “comprehensive and critical analysis” are not available in the prompt.

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Valneva Austria Gmbh	IXIARO	japanese encephalitis vaccine, inactivated, adsorbed	Injection	125280	30-Mar-09	6,309,650	2018-08-25
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Applicant

Tradename

Biologic Ingredient

Dosage Form

BLA

Approval Date

Patent No.

Expiredate

Valneva Austria Gmbh

IXIARO

japanese encephalitis vaccine, inactivated, adsorbed

Injection

125280

30-Mar-09

6,309,650

2018-08-25

>Applicant

>Tradename

>Biologic Ingredient

>Dosage Form

>BLA

>Approval Date

>Patent No.

>Expiredate

Subscribe to access the full database, or Start Trial

Title:	Attenuated Japanese encephalitis virus adapted to Vero cell and a Japanese encephalitis vaccine
Abstract:	An attenuated Japanese encephalitis virus adapted to Vero cell by passages on Vero cell is disclosed. A Japanese encephalitis vaccine comprising said attenuated virus is also disclosed.
Inventor(s):	Hyun Su Kim, Wang Don Yoo, Soo Ok Kim, Sung Hee Lee, Sang Bum Moon, Sun Pyo Hong, Yong Cheol Shin, Yong Ju Chung, Kenneth H. Eckels, Bruce Innis, Joseph R. Puniak, Leonard N. Binn, Ashok K. Srivastava, Doria R. Dubois
Assignee:	CJ Corp , United States Department of the Army
Application Number:	US09/486,392
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	US Patent 6,309,650: What Claims Does It Cover and How Does Its US Patent Landscape Shape Freedom-to-Operate? US Patent 6,309,650 (granted Oct. 30, 2001) anchors a US claim set that remains relevant for freedom-to-operate (FTO) analysis primarily through (i) the original asserted claim scope at issuance, (ii) related continuations/divisionals and continuations-in-part that may have expanded claim coverage, and (iii) later refinement patents by the same assignees or competitors on the same technical core. Without the patent’s full specification and claim text, a claim-by-claim legal construction or an expiration/term and exclusivity mapping cannot be produced accurately, and the landscape cannot be tied to the correct CPC/US classes or to actual citing and family members. No response is provided because the necessary claim text, assignee, publication family, and prosecution history details required to deliver a complete and accurate “comprehensive and critical analysis” are not available in the prompt. More… ↓ ⤷ Start Trial

Patent: 6,309,650

Summary for Patent: 6,309,650

Details for Patent 6,309,650

Make Better Decisions: Try a trial or see plans & pricing